Citations

Clear

6274 citation(s) found for "To, Andrew".

TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis
Kassab, Ihab , Massani, Marco , Townsend, Whitney , Singal, Amit G. , Moreno-Luna, Laura E., Roberts, Lewis R. , Chen, Vincent , Parikh, Neehar D. , Singal, Amit , Moreno-Luna, Laura, Parikh, Neehar D , Roberts, Lewis R , Chen, V L , Brown, Andrew M K , Soydal, Çiğdem

Mayo Clinic

Cancer Medicine | August 9, 2022 | Volume: 12 | Issue: 3 | Pages: 2590-2599

10.1002/cam4.5125 | PMID 35943116 Get It

AbstractBackgroundTransarterial radioembolization (TARE) is increasingly used as an alternative to transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). We aimed to perform an overall and individual patient data (IPD) meta‐analysis of studies comparing TACE and TARE.MethodsWe performed a systematic literature search using pre‐specified keywords with the aid of an informationist for articles from inception to 3/2020. The primary endpoint was overall survival (OS), and the secondary endpoint was time to progression (TTP).ResultsSeventeen studies met inclusion criteria with 2465 unique patients, with one randomized trial, 4 prospective studies and 12 retrospective studies. Barcelona Clinic Liver Cancer (BCLC) stage B (42.8%) was the most common stage followed by BCLC A (30.3%) and BCLC C (29.0%). There was no difference in OS between the two modalities (−0.55 months, 95% CI −1.95 to 3.05). In three studies with available TTP data, TARE resulted in a longer TTP than TACE (mean TTP 17.5 vs. 9.8 months; mean TTP difference 4.8 months, 95% CI 1.3–8.3 months). IPD‐level meta‐analysis of 311 patients from three studies showed no difference in overall OS between the two modalities including among subgroups stratified by tumor stage and liver function. Limitations of the current literature include inconsistent length of follow‐up, inconsistency in response criteria, and safety reporting.ConclusionsCurrent data suggest TARE provides significantly longer TTP than TACE, although the two treatments do not significantly differ in terms of OS. Given limitations of the current data, there is rationale for prospective studies comparing these modalities.
Dismissal disagreement and discharge delays: Associations of patient–clinician plan of care agreement with discharge outcomes
Olson, Emily M. , Falde, Samuel D., Wegehaupt, Abigail K., Halvorsen, Andrew J. , Lawson, Donna K. , Ratelle, John T. , Ratelle, John T , Polley, Eric C.

Mayo Clinic

Journal of Hospital Medicine | August 9, 2022 | Volume: 17 | Issue: 9 | Pages: 710-718

10.1002/jhm.12929 | PMID 35942985 Get It

AbstractBackgroundMany hospitalized patients do not understand or agree with their clinicians about their discharge plan. However, the effect of disagreement on discharge outcomes is unknown.ObjectiveTo measure the correlation between patient‐clinician care agreement and discharge outcomes.DesignA prospective cohort study was performed from September 2019 to March 2020 (Rochester, MN, USA).Setting and ParticipantsInternal medicine patients and their primary clinician (resident, advanced practice clinician or attending) hospitalized from September 2019‐March 2020 at Mayo Clinic Hospital. Participants were independently surveyed following hospital day #3 ward rounds regarding the goals of the hospitalization and discharge planning.Main Outcome and MeasuresPatient–clinician agreement for main diagnosis, patient's main concern, and four domains of discharge planning was assessed. Readiness for hospital discharge, delayed discharge, and 30‐day readmission was measured. Then, associations between patient‐clinician agreement, delayed discharge, and 30‐day readmissions were analyzed using multivariable logistic regression.ResultsOf the 436 patients and clinicians, 17.7% completely agreed about what needs to be accomplished before dismissal, 40.8% agreed regarding discharge date, and 71.1% agreed regarding discharge location. In the multivariable model, patient–clinician agreement scores were not significantly correlated with discharge outcomes. Patient–clinician agreement on discharge location was higher for those discharged to home (81.5%) versus skilled nursing facility (48.5%) or assisted living (42.9%) (p < .0001). The agreement on the expected length of stay was highest for home‐goers (45.9%) compared to skilled nursing (32.0%) or assisted living (21.4%) (p = .004).ConclusionsPatients and their clinicians frequently disagree about when and where a patient will go after hospitalization, particularly for those discharged to a skilled nursing facility. While disagreement did not predict discharge outcomes, our findings suggest opportunities to improve effective communication and promote shared mental models regarding discharge earlier in the hospital stay.
Immunohistochemical Approach to Genetic Subtyping of Anaplastic Large Cell Lymphoma
Ansell, Stephen M. , Dasari, Surendra , Feldman, Andrew L. , Oishi, Naoki , Ketterling, Rhett P. , Shi, Min

Mayo Clinic

American Journal of Surgical Pathology | August 9, 2022 | Volume: 46 | Issue: 11 | Pages: 1490-1499

10.1097/pas.0000000000001941 | PMID 35941721 Get It

Anaplastic large cell lymphoma (ALCL) can be classified genetically based on rearrangements (R) of the ALK, TP63, and/or DUSP22 genes. ALK-R defines a specific entity, ALK-positive ALCL, while DUSP22-R and TP63-R define subgroups of ALK-negative ALCLs with distinct clinicopathologic features. ALK-R and TP63-R produce oncogenic fusion proteins that can be detected by immunohistochemistry. ALK immunohistochemistry is an excellent surrogate for ALK-R and screening with p63 immunohistochemistry excludes TP63-R in two third of ALCLs. In contrast, DUSP22-R does not produce a fusion protein and its identification requires fluorescence in situ hybridization. However, DUSP22-R ALCL has a characteristic phenotype including negativity for cytotoxic markers and phospho-STAT3Y705. Recently, we also identified overexpression of the LEF1 transcription factor in DUSP22-R ALCL. Here, we sought to validate this finding and examine models for predicting DUSP22-R using immunohistochemistry for LEF1 and TIA1 or phospho-STAT3Y705. We evaluated these 3 markers in our original discovery cohort (n=45) and in an independent validation cohort (n=46) of ALCLs. The correlation between DUSP22-R and LEF1 expression replicated strongly in the validation cohort (P<0.0001). In addition, we identified and validated a strategy using LEF1 and TIA1 immunohistochemistry that predicted DUSP22-R with positive and negative predictive values of 100% after exclusion of indeterminate cases and would eliminate the need for fluorescence in situ hybridization in 65% of ALK-negative ALCLs. This approach had similar results in identifying DUSP22-R in the related condition, lymphomatoid papulosis. Together with previous data, these findings support a 4-marker immunohistochemistry algorithm using ALK, LEF1, TIA1, and p63 for genetic subtyping of ALCL.
Left ventricular assist devices: A historical perspective at the intersection of medicine and engineering
Goodman, Daniel , Stulak, John M., Rosenbaum, Andrew , Rosenbaum, Andrew N

Mayo Clinic

Artificial Organs | August 5, 2022 | Volume: 46 | Issue: 12 | Pages: 2343-2360

10.1111/aor.14371 | PMID 35929377 Get It

AbstractOver the last half‐century, left ventricular assist device (LVAD) technology has progressed from conceptual therapy for failed cardiopulmonary bypass weaning to an accepted destination therapy for advanced heart failure. The history of LVAD engineering is defined by an initial development phase, which demonstrated the feasibility of such an approach, to the more recent three major generations of commercial devices. In this review, we explore the engineering challenges of LVADs, how they were addressed over time, and the clinical outcomes that resulted from each major technological development. The first generation of commercial LVADs were pulsatile devices, which lacked the appropriate durability due to their number of moving components and hemocompatibility. The second generation of LVADs was defined by replacement of complex, pulsatile pumps with primarily axial, continuous‐flow systems with an impeller in the blood passageway. These devices experienced significant commercial success, but the presence of excessive trauma to the blood and in‐situ bearing resulted in an unacceptable burden of adverse events. Third generation centrifugal‐flow pumps use magnetically suspended rotors within the pump chamber. Superior outcomes with this newest generation of devices have been observed, particularly with respect to hemocompatibility‐related adverse events including pump thrombosis, with fully magnetically levitated devices. The future of LVAD engineering includes wireless charging foregoing percutaneous drivelines and more advanced pump control mechanisms, including synchronization of the pump flow with the native cardiac cycle, and varying pump output based on degree of physical exertion using sensor or advanced device‐level data triggers.
Pulmonary Vascular Research Institute GoDeep: A meta‐registry merging deep phenotyping datafrom international PH reference centers
Majeed, Raphael W. , Anthi, Anastasia , Cannon, John, Chan, Stephen Y. , Damonte, Victoria , Elwing, Jean , Förster, Kai , Ghouleh, Imad Al , Juaneda, Ernesto , Kiely, David G. , Orfanos, Stylianos E. , Pepe, Antonella, Sіrenko, Yu.M. , Swett, Andrew J., Zamanian, Roham T. , Marquardt, Kurt , Michel‐Backofen, Achim, Antoine, Tobiah, Wilhelm, Jochen , Barwick, Stephanie , Krieb, Phillipp, Fuenderich, Meike, Ghofrani, Hossein‐Ardeschir, Tello, Khodr , Richter, Manuel J. , Seeger, Werner , Sweatt, Andrew J. , Chan, Stephen Y , Frantz, Robert P , Jose, Arun , Lawrie, Allan , Gall, Henning , Seeger, Werner , Kiely, David , Majeed, Raphael W , Wilkins, Martin R. , Howard, Luke , Hassoun, Paul M. , Cajigas, Héctor , Frantz, Robert P. , Ghio, Stefano , Hilgendorff, Anne , Jose, Arun , Pepe, Antonella, Pepke‐Żaba, Joanna , Torbas, O.O. , Michel-Backofen, Achim, Barwick, Stephanie, Fünderich, Meike , Fischer, Patrick, Gall, Henning , Ghofrani, Hossein‐Ardeschir, Grimminger, Friedrich

Mayo Clinic

Pulmonary Circulation | August 3, 2022 | Volume: 12 | Issue: 3 | Pages: No page available

10.1002/pul2.12123 | PMID 36034404 Get It

AbstractThe Pulmonary Vascular Research Institute GoDeep meta‐registry is a collaboration of pulmonary hypertension (PH) reference centers across the globe. Merging worldwide PH data in a central meta‐registry to allow advanced analysis of the heterogeneity of PH and its groups/subgroups on a worldwide geographical, ethnical, and etiological landscape (ClinTrial. gov NCT05329714). Retrospective and prospective PH patient data (diagnosis based on catheterization; individuals with exclusion of PH are included as a comparator group) are mapped to a common clinical parameter set of more than 350 items, anonymized and electronically exported to a central server. Use and access is decided by the GoDeep steering board, where each center has one vote. As of April 2022, GoDeep comprised 15,742 individuals with 1.9 million data points from eight PH centers. Geographic distribution comprises 3990 enrollees (25%) from America and 11,752 (75%) from Europe. Eighty‐nine perecent were diagnosed with PH and 11% were classified as not PH and provided a comparator group. The retrospective observation period is an average of 3.5 years (standard error of the mean 0.04), with 1159 PH patients followed for over 10 years. Pulmonary arterial hypertension represents the largest PH group (42.6%), followed by Group 2 (21.7%), Group 3 (17.3%), Group 4 (15.2%), and Group 5 (3.3%). The age distribution spans several decades, with patients 60 years or older comprising 60%. The majority of patients met an intermediate risk profile upon diagnosis. Data entry from a further six centers is ongoing, and negotiations with >10 centers worldwide have commenced. Using electronic interface‐based automated retrospective and prospective data transfer, GoDeep aims to provide in‐depth epidemiological and etiological understanding of PH and its various groups/subgroups on a global scale, offering insights for improved management.
Prognostic Implications of a Morphometric Evaluation for Chronic Changes on All Diagnostic Native Kidney Biopsies
Đenić, Aleksandar , Bogojevic, Marija , Sabov, Moldovan, Asghar, Muhammad Sohaib , Sethi, Sanjeev , Fervenza, Fernando C. , Glassock, Richard J. , Asghar, Muhammad S , Rule, Andrew D , Fervenza, Fernando C , Denic, Aleksandar , Mullan, Aidan F. , Smith, Maxwell L. , Hommos, Musab S. , Rule, Andrew D.

Mayo Clinic

Journal of the American Society of Nephrology | August 3, 2022 | Volume: 33 | Issue: 10 | Pages: 1927-1941

10.1681/asn.2022030234 | PMID 35922132 Get It

Background Semiquantitative visual inspection for glomerulosclerosis, interstitial fibrosis, and arteriosclerosis is often used to assess chronic changes in native kidney biopsies. Morphometric evaluation of these and other chronic changes may improve the prognostic assessment. Methods We studied a historical cohort of patients who underwent a native kidney biopsy between 1993 and 2015 and were followed through 2021 for ESKD and for progressive CKD (defined as experiencing 50% eGFR decline, temporary dialysis, or ESKD). Pathologist scores for the percentages of globally sclerosed glomeruli (GSG), interstitial fibrosis and tubular atrophy (IFTA), and arteriosclerosis (luminal stenosis) were available. We scanned biopsy sections into high-resolution images to trace microstructures. Morphometry measures were percentage of GSG; percentage of glomerulosclerosis (percentage of GSG, ischemic-appearing glomeruli, or segmentally sclerosed glomeruli); percentage of IFTA; IFTA foci density; percentage of artery luminal stenosis; arteriolar hyalinosis counts; and measures of nephron size. Models assessed risk of ESKD or progressive CKD with biopsy measures adjusted for age, hypertension, diabetes, body mass index, eGFR, and proteinuria. Results Of 353 patients (followed for a median 7.5 years), 75 developed ESKD and 139 experienced progressive CKD events. Visually estimated scores by pathologists versus morphometry measures for percentages of GSG, IFTA, and luminal stenosis did not substantively differ in predicting outcomes. However, adding percentage of glomerulosclerosis, IFTA foci density, and arteriolar hyalinosis improved outcome prediction. A 10-point score using percentage of glomerulosclerosis, percentage of IFTA, IFTA foci density, and any arteriolar hyalinosis outperformed a 10-point score based on percentages of GSG, IFTA, and luminal stenosis >50% in discriminating risk of ESKD or progressive CKD. Conclusion Morphometric characterization of glomerulosclerosis, IFTA, and arteriolar hyalinosis on kidney biopsy improves prediction of long-term kidney outcomes.
Standardization of serum creatinine is essential for accurate use of unbiased estimated GFR equations: evidence from three cohorts matched on renal function
Pottel, Hans , Cavalier, Etienne , Björk, Jonas , Grubb, Anders , Ebert, Natalie , Schäeffner, Elke , Melsom, Toralf , Lamb, Edmund J. , Mariat, Christophe , Dubourg, Laurence , Hansson, Magnus , Littmann, Karin , Sundin, Per‐Ola , Åkesson, Anna , Ebert, Natalie , Sundin, Per-Ola , Delanaye, Pierre , Grubb, Anders , Schaeffner, Elke , Björk, Jonas , Nyman, Ulf , Eriksen, Björn O. , Larsson, Anders , Rule, Andrew D. , Delanaye, Pierre

Mayo Clinic

Clinical Kidney Journal | August 3, 2022 | Volume: 15 | Issue: 12 | Pages: 2258-2265

10.1093/ckj/sfac182 | PMID 36381377 Get It

ABSTRACT Background Differences in the performance of estimated glomerular filtration rate (eGFR) equations have been attributed to the mathematical form of the equations and to differences between patient demographics and measurement methods. We evaluated differences in serum creatinine (SCr) and eGFR in cohorts matched for age, sex, body mass index (BMI) and measured GFR (mGFR). Methods White North Americans from Minnesota (n = 1093) and the Chronic Renal Insufficiency Cohort (CRIC) (n = 1548) and White subjects from the European Kidney Function Consortium (EKFC) cohort (n = 7727) were matched for demographic patient characteristics (sex, age ± 3 years, BMI ± 2.5 kg/m2) and renal function (mGFR ± 3 ml/min/1.73 m2). SCr was measured with isotope dilution mass spectrometry (IDMS)-traceable assays in the Minnesota and EKFC cohorts and with non-standardized SCr assays recalculated to IDMS in the CRIC. The Minnesota cohort and CRIC shared a common method to measure GFR (renal clearance of iothalamate), while the EKFC cohort used a variety of exogenous markers and methods, all with recognized sufficient accuracy. We compared the SCr levels and eGFR predictions [for Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and EKFC equations] of patients fulfilling these matching criteria. Results For 305 matched individuals, mean SCr (mg/dL) was not different between the Minnesota and EKFC cohorts (females 0.83 ± 0.20 versus 0.86 ± 0.23, males 1.06 ± 0.23 versus 1.12 ± 0.37; P &gt; .05) but significantly different from the CRIC [females 1.13 ± 0.23 (P &lt; .0001), males 1.42 ± 0.31 (P &lt; .0001)]. The CKD-EPI equations performed better than the EKFC equation in the CRIC, while the opposite was true in the Minnesota and EKFC cohorts. Conclusion Significant differences in SCr concentrations between the Minnesota and EKFC cohorts versus CRIC were observed in subjects with the same level of mGFR and equal demographic characteristics and can be explained by the difference in SCr calibration.
Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism
Minisola, Salvatore , Arnold, Andrew , Clarke, B.L. , Hannan, Fadil , Hofbauer, Lorenz C. , Liberman, Uri , Palermo, Andrea , Pepe, Jessica , Rizzoli, René , Wermers, Robert A. , Brandi, Maria Luisa , Clarke, Bart L , Hannan, Fadil M , Hofbauer, Lorenz C , Insogna, Karl , Palermo, Andrea , Pepe, Jessica , Wermers, Robert, Thakker, Rajesh V , Belaya, Zhanna E. , Brandi, Maria Luisa , Lacroix, André , Thakker, Rajesh V.

Mayo Clinic

Journal of Bone and Mineral Research | August 3, 2022 | Volume: 37 | Issue: 11 | Pages: 2315-2329

10.1002/jbmr.4665 | PMID 36245271 Get It

ABSTRACT In this narrative review, we present data gathered over four decades (1980–2020) on the epidemiology, pathophysiology and genetics of primary hyperparathyroidism (PHPT). PHPT is typically a disease of postmenopausal women, but its prevalence and incidence vary globally and depend on a number of factors, the most important being the availability to measure serum calcium and parathyroid hormone levels for screening. In the Western world, the change in presentation to asymptomatic PHPT is likely to occur, over time also, in Eastern regions. The selection of the population to be screened will, of course, affect the epidemiological data (ie, general practice as opposed to tertiary center). Parathyroid hormone has a pivotal role in regulating calcium homeostasis; small changes in extracellular Ca++ concentrations are detected by parathyroid cells, which express calcium-sensing receptors (CaSRs). Clonally dysregulated overgrowth of one or more parathyroid glands together with reduced expression of CaSRs is the most important pathophysiologic basis of PHPT. The spectrum of skeletal disease reflects different degrees of dysregulated bone remodeling. Intestinal calcium hyperabsorption together with increased bone resorption lead to increased filtered load of calcium that, in addition to other metabolic factors, predispose to the appearance of calcium-containing kidney stones. A genetic basis of PHPT can be identified in about 10% of all cases. These may occur as a part of multiple endocrine neoplasia syndromes (MEN1–MEN4), or the hyperparathyroidism jaw-tumor syndrome, or it may be caused by nonsyndromic isolated endocrinopathy, such as familial isolated PHPT and neonatal severe hyperparathyroidism. DNA testing may have value in: confirming the clinical diagnosis in a proband; eg, by distinguishing PHPT from familial hypocalciuric hypercalcemia (FHH). Mutation-specific carrier testing can be performed on a proband's relatives and identify where the proband is a mutation carrier, ruling out phenocopies that may confound the diagnosis; and potentially prevention via prenatal/preimplantation diagnosis. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). Abstract The prevalence and incidence of PHPT vary around the world and depend on a number of factors, the most important being availability of serum calcium (and parathyroid hormone) measurement for screening, which in the Western world has shifted its presentation to an asymptomatic disorder. Clonally dysregulated overgrowth of one or more parathyroid glands together with reduced expression of CaSRs is the most important pathophysiologic basis of PHPT, which may also occur as a part of inherited syndromes or as a nonsyndromic isolated endocrinopathy in 10% of cases. Genetic testing has roles in establishing the clinical diagnosis, although its value requires assessments using GRADE(176) methodology, which is recommended for future consideration.
Assessment of Electronic Health Record for Cancer Research and Patient Care Through a Scoping Review of Cancer Natural Language Processing
Wang, Liwei , Fu, Sunyang , Wen, Andrew , Ruan, Xiaoyang , Liu, Sijia , Moon, Sungrim , Mai, Michelle , Riaz, Irbaz Bin , Wang, Nan , Xu, Hua , He, Huan , Liu, Sijia , Moon, Sungrim , Riaz, Irbaz B , Yang, Ping , Warner, Jeremy L , Liu, Hongfang , Fu, Sunyang , Wen, Andrew , He, Huan , Yang, Ping , Warner, Jeremy L. , Liu, Hongfang

Mayo Clinic

JCO Clinical Cancer Informatics | August 2, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/cci.22.00006 | PMID 35917480 Get It

PURPOSEThe advancement of natural language processing (NLP) has promoted the use of detailed textual data in electronic health records (EHRs) to support cancer research and to facilitate patient care. In this review, we aim to assess EHR for cancer research and patient care by using the Minimal Common Oncology Data Elements (mCODE), which is a community-driven effort to define a minimal set of data elements for cancer research and practice. Specifically, we aim to assess the alignment of NLP-extracted data elements with mCODE and review existing NLP methodologies for extracting said data elements.METHODSPublished literature studies were searched to retrieve cancer-related NLP articles that were written in English and published between January 2010 and September 2020 from main literature databases. After the retrieval, articles with EHRs as the data source were manually identified. A charting form was developed for relevant study analysis and used to categorize data including four main topics: metadata, EHR data and targeted cancer types, NLP methodology, and oncology data elements and standards.RESULTSA total of 123 publications were selected finally and included in our analysis. We found that cancer research and patient care require some data elements beyond mCODE as expected. Transparency and reproductivity are not sufficient in NLP methods, and inconsistency in NLP evaluation exists.CONCLUSIONWe conducted a comprehensive review of cancer NLP for research and patient care using EHRs data. Issues and barriers for wide adoption of cancer NLP were identified and discussed.
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project
Midgette, Bria, Strunk, Andrew , Akilov, Oleg E. , Ardon, Christine B. , Cohen, Arnon D. , Cohen, Steven A. , Daveluy, Steven , Delage, M. , Esmann, Solveig, Fisher, Shani , Głowaczewska, Amelia , Brant, Elena Gonzalez, Guilbault, Sandra , Hughes, Rosalind , Ingram, John R , Jemec, Gregor B. E. , Ju, Qiang , Kappe, Naomi , Kirby, Joslyn S. , Matusiak, Łukasz , Micha, Stella, Miller, Angela P., Moseng, Dagfinn, Naik, Haley B. , Nassif, Aude , Nikolakis, Georgios , Pascual, J.C. , Resnik, Barry I., Riad, Hassan, Sayed, Christopher J. , Soliman, Yssra , Szepietowski, Jacek C. , Thorlacius, Linnea , Zee, Hessel H. van der , Villumsen, Bente , Wang, Lanqi , Garg, Amit , Cohen, Steven , Daveluy, Steven , Ingram, J R , Jemec, G B E , Micheletti, Robert , Naik, Haley , Paek, So Yeon , Sayed, Christopher , Szepietowski, Jacek C , Wang, Lanqi , Garg, Amit , Thorlacius, L , Akilov, Oleg E , van der Zee, Hessel H , Alavi, Afsáneh , Bechara, Falk G. , Mármol, V. del , Giamarellos‐Bourboulis, Evangelos J. , Goldfarb, Noah , Grimstad, Øystein , Hamzavi, Iltefat H. , Kirby, Brian , Lowes, Michelle A , Paek, So Yeon , Prens, Errol P. , Smith, Saxon D. , Tan, Jerry K.L. , Tzellos, Thrasyvoulos , Zouboulis, Christos C.

Mayo Clinic

British Journal of Dermatology | July 30, 2022 | Volume: 187 | Issue: 6 | Pages: 927-935

10.1111/bjd.21798 | PMID 36056741 Get It

Abstract Background Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored. Objectives To measure associations between treatment satisfaction and clinical and treatment-related characteristics among patients with HS. Methods Treatment satisfaction was evaluated utilizing data from a cross-sectional global survey of patients with HS recruited from 27 institutions, mainly HS referral centres, in 14 different countries from October 2017 to July 2018. The primary outcome was patients’ self-reported overall satisfaction with their current treatments for HS, rated on a five-point scale from ‘very dissatisfied’ to ‘very satisfied’. Results The final analysis cohort comprised 1418 patients with HS, most of whom were European (55%, 780 of 1418) or North American (38%, 542 of 1418), and female (85%, 1210 of 1418). Overall, 45% (640 of 1418) of participants were either dissatisfied or very dissatisfied with their current medical treatment. In adjusted analysis, patients primarily treated by a dermatologist for HS had 1·99 [95% confidence interval (CI) 1·62–2·44, P &lt; 0·001] times the odds of being satisfied with current treatment than participants not primarily treated by a dermatologist. Treatment with biologics was associated with higher satisfaction [odds ratio (OR) 2·36, 95% CI 1·74–3·19, P &lt; 0·001] relative to treatment with nonbiologic systemic medications. Factors associated with lower treatment satisfaction included smoking (OR 0·78, 95% CI 0·62–0·99; active vs. never), depression (OR 0·69, 95% CI 0·54–0·87), increasing number of comorbidities (OR 0·88 per comorbidity, 95% CI 0·81–0·96) and increasing flare frequency. Conclusions There are several factors that appear to positively influence satisfaction with treatment among patients with HS, including treatment by a dermatologist and treatment with a biologic medication. Factors that appear to lower treatment satisfaction include active smoking, depression, accumulation of comorbid conditions and increasing flare frequency. Awareness of these factors may support partnered decision making with the goal of improving treatment outcomes. What is already known about this topic? Nearly half of patients with hidradenitis suppurativa report dissatisfaction with their treatments. What does this study add? Satisfaction with treatment is increased by receiving care from a dermatologist and treatment with biologics.Satisfaction with treatment is decreased by tobacco smoking, accumulation of comorbid conditions including depression, and higher flare frequency. What are the clinical implications of this work? Awareness of the identified factors associated with poor treatment satisfaction may support partnered decision making and improve treatment outcomes.